Sage Therapeutics/$SAGE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sage Therapeutics
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Ticker
$SAGE
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
353
ISIN
US78667J1088
Website
SAGE Metrics
BasicAdvanced
$579M
-
-$5.79
0.48
-
Price and volume
Market cap
$579M
Beta
0.48
52-week high
$13.47
52-week low
$4.62
Average daily volume
1.9M
Financial strength
Current ratio
9.13
Quick ratio
8.785
Long term debt to equity
2.45
Total debt to equity
2.893
Profitability
EBITDA (TTM)
-358.976
Gross margin (TTM)
-291.84%
Net profit margin (TTM)
-747.61%
Operating margin (TTM)
-758.97%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-36.35%
Return on equity (TTM)
-63.53%
Valuation
Price to revenue (TTM)
11.941
Price to book
1.41
Price to tangible book (TTM)
1.41
Price to free cash flow (TTM)
-1.82
Free cash flow yield (TTM)
-54.96%
Free cash flow per share (TTM)
-508.35%
Growth
Revenue change (TTM)
-47.94%
Earnings per share change (TTM)
-31.00%
3-year revenue growth (CAGR)
95.88%
3-year earnings per share growth (CAGR)
-11.05%
10-year earnings per share growth (CAGR)
13.04%
What the Analysts think about SAGE
Analyst ratings (Buy, Hold, Sell) for Sage Therapeutics stock.
Bulls say / Bears say
Sage Therapeutics' postpartum depression drug, Zurzuvae, received FDA approval in August 2023, positioning the company to address a significant unmet need in women's mental health. (businesswire.com)
The company has implemented a strategic reorganization, including a 40% workforce reduction, to streamline operations and focus resources on the successful launch of Zurzuvae, potentially leading to improved financial performance. (businesswire.com)
Sage's rejection of Biogen's $469 million acquisition offer in January 2025 suggests confidence in its valuation and future prospects, indicating potential for higher shareholder value. (reuters.com)
The FDA's rejection of Zurzuvae for major depressive disorder in 2023 limits the drug's market potential, focusing it solely on postpartum depression and narrowing revenue opportunities. (bizjournals.com)
Sage reported a net loss of $400.7 million in 2024, with an accumulated deficit of $3.0 billion, raising concerns about the company's financial sustainability. (thecrimson.com)
The failure of the Phase 2 LIGHTWAVE study for dalzanemdor in October 2024 led to a reduced price target for Sage, reflecting diminished investor confidence in the company's pipeline. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
SAGE Financial Performance
Revenues and expenses
SAGE Earnings Performance
Company profitability
SAGE News
AllArticlesVideos
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
Business Wire·1 week ago
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
Benzinga·1 week ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect
Accesswire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sage Therapeutics stock?
Sage Therapeutics (SAGE) has a market cap of $579M as of June 26, 2025.
What is the P/E ratio for Sage Therapeutics stock?
The price to earnings (P/E) ratio for Sage Therapeutics (SAGE) stock is 0 as of June 26, 2025.
Does Sage Therapeutics stock pay dividends?
No, Sage Therapeutics (SAGE) stock does not pay dividends to its shareholders as of June 26, 2025.
When is the next Sage Therapeutics dividend payment date?
Sage Therapeutics (SAGE) stock does not pay dividends to its shareholders.
What is the beta indicator for Sage Therapeutics?
Sage Therapeutics (SAGE) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.